New clinical data presented at ECO 2026 and published in Nature Medicine suggest that weight loss achieved on injectable obesity therapies can be maintained by transitioning to oral treatment. The findings include evidence for sustained weight reduction when moving to daily oral orforglipron (ATTAIN-MAINTAIN), positioning oral “maintenance” as a strategy to reduce reliance on injectables long-term. Separately, other ECO-released results point to continuing maximum-dose tirzepatide as another maintenance approach, underscoring that trial design choices—dose continuity versus switch—may drive different durability profiles. For payers and providers, these findings add practical options to the obesity care pathway: tapering away from injections without losing the weight-loss plateau.